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Abstract
Aim The ACROPRAXIS program aims to describe the management of acromegaly in Spain and provide guidance.
Methods Ninety-three endocrinologists were organized into 13 panels to discuss the practical issues in managing acromeg-
aly. Based on the key learnings, an online Delphi survey with 62 statements was performed, so those statements achieving 
consensus could be used as guidance. Statements were rated on a 9-point scale (9, full agreement; consensus > 66.6% of 
response in the same tertile).
Results Ninety-two endocrinologists (98.8%) answered two rounds of the survey (mean age 47.6 years; 59.8% women; 
median 18.5 years of experience). Consensus was achieved for 49 (79%) statements. Diagnosis: The levels of insulin-like 
growth factor I (IGFI) is the preferred screening test. If IGFI levels 1–1.3 ULN, the test is repeated and growth hormone 
(GH) after oral glucose tolerance test (OGTT) is assessed. A pituitary magnetic resonance is performed after biochemical 
diagnosis. Treatment: Surgery is the first treatment choice for patients with microadenoma or macroadenoma with/with-
out optical pathway compression. Pre-surgical somatostatin analogues (SSA) are indicated when surgery is delayed and/
or to reduce anaesthesia-associated risks. After unsuccessful surgery, reintervention is performed if the residual tumor is 
resectable, while if non-resectable, SSA are administered. Follow-up First biochemical and clinical controls are performed 
1–3 months after surgery. Disease remission is considered if random GH levels are < 1 µg/L or OGTT is < 1 or ≤ 0.4 µg/L, 
depending on the assay’s sensitivity.
Conclusion Current clinical management for acromegaly is homogeneous across Spain and generally follows clinical 
guidelines.
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Introduction
Acromegaly is a disease characterized by growth hormone 
(GH) hypersecretion, usually due to a pituitary adenoma, 
which causes disproportionate skeletal, soft tissue, and 
organ growth, resulting in multisystem-associated comor-
bidities, including hypertension, diabetes, sleep apnea, 
arthropathy, and increased mortality [1, 2]. There are no 
pathognomonic features and the symptoms progress insidi-
ously; thus, the diagnosis is usually delayed (a median of 
10 years in women and 8 years in men) [3, 4]. The average 
age at presentation ranges from 40 to 50 years old [4], and 
the most frequent presenting signs/symptoms are changes 
in physical appearance (dysmorphic features and exces-
sive growth of hands and feet), headache, fatigue/asthe-
nia, sweating, sleep apnea, and menstrual disturbances 
in women [3]. Diagnosis is confirmed by high levels of 
GH and insulin-like growth factor I (IGFI), which pro-
vides a measure of integrated GH secretion [5–7]. Treat-
ment includes three different therapies: surgery, medical 
treatment (somatostatin analogues [SSA], the human GH 
receptor antagonist pegvisomant, and the dopaminergic 
agonist cabergoline) and radiotherapy (RT) [5–7].
When and how to apply the different treatment modali-
ties, as well as the specific GH and IGFI values and 
measurement method for diagnosis, plus the patient man-
agement during follow-up are detailed in the available 
acromegaly guidelines [5–7]. However, in acromegaly, as 
in other diseases, real life practice does not always follow 
clinical guidelines [8]. In this regard, the implementation 
of acromegaly guidelines to the clinical practice in Spain 
might be limited in certain hospitals due to logistical-
related issues, and thus, it was of interest to describe the 
current Spanish clinical practice. Once described, the com-
mon practices could be submitted to a Delphi survey and 
those achieving consensus could be used to provide local 
guidance for the management of acromegaly, while tak-
ing under consideration the current state of healthcare and 
clinical practice in Spain (ACROPRAXIS program). Due 
to the diversity of resources access and clinical practices 
in Europe, sharing this information might be of interest to 
compare the practice of other groups in other countries.
Materials and methods
The ACROPRAXIS program was conducted in two phases. 
In the first phase, we aimed to define the current clini-
cal practice in Spain. A scientific committee of 11 expert 
endocrinologists developed an online questionnaire with 
45 questions about the diagnosis, treatment and follow-up 
of acromegaly. The questionnaire was anonymously 
answered by 93 endocrinologists, with at least 5 years of 
experience in acromegaly, from different geographic areas 
of Spain, grouped in 13 region panels. The results were 
discussed by the panelists in regional meetings, with a spe-
cial attention to those issues in which the reported clinical 
practice was less homogeneous or was different from the 
guidelines´ recommendations.
Based on the conclusions of the regional meetings, the 
scientific committee gathered the common practices on the 
management of acromegaly, which, in the second phase of 
the program, had to be validated by all the panelists fol-
lowing the Delphi methodology (a reliable technique for 
reaching a consensus among a panel of experts) [9]. The 
online Delphi survey consisted on 62 statements regard-
ing diagnosis (18 statements), treatment (25) and follow-up 
(19). The 93 participants were asked to rate each statement 
anonymously on a Likert-like scale from 1 (“completely dis-
agree”) to 9 (“completely agree”). Responses were grouped 
by tertiles: 1–3: Disagreement (D), 4–6: Indeterminate (I) 
(no agreement or disagreement), 7–9: Agreement (A). Con-
sensus (C) on a statement was reached when the responses of 
2/3 or more participants (≥ 66.6%) were in the same tertile 
as the median value of all the reported responses for that 
statement.
Statistical analysis
A descriptive analysis of all items using the mean (± stand-
ard deviation), median (interquartile range; IQR), and mini-
mum and maximum values was performed. The Kolmogo-
rov–Smirnov test was used to check for goodness of fit of 
the data to a normal distribution.
The internal consistency of the questionnaire was 
measured by the Cronbach’s alpha (Cα), which can range 
between 0 and 1, from lower to greater reliability (accept-
able values: > 0.7, high reliability: 0.7–0.9, very high reli-
ability > 0.9) [10]. In addition, inter-rater reliability was 
assessed by the intra-class correlation coefficient  (ri) (poor: 
 ri < 0.40, fair:  ri = 0.40–0.59, good:  ri = 0.60–0.74, and excel-
lent:  ri = 0.75–1.0) [11].
The correlation between the two rounds of the question-
naire was measured by the Spearman coefficient  (rs) (none or 
poor:  rs = 0–0.25, weak:  rs = 0.26–0.50, moderate to strong: 
 rs = 0.51–0.75, and strong to very strong:  rs = 0.76–1) [12]. 
The Kappa index (k) was calculated to estimate the quali-
tative agreement between the rounds having into account 
the three answer groups (1–3, 4–6 and 7–9) (none or poor: 
k < 0.20, weak = 0.21 to 0.40, moderate: k = 0.41 to 0.60, 
good: k = 0.61 to 0.80, and very good: k = 0.81 to 1) [13]. 
All these values were calculated for the overall survey and 
for each of the three blocks (diagnosis, treatment and follow-
up). Statistical significance was considered when p < 0.05.
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The variation coefficient (VC) of the questionnaire was 
calculated for every round, along with the delta or relative 
increase in the second round above the first (VC second-VC 
first/VC first). When delta is < 10%, there is no large vari-
ability between the rounds, and thus, there is no need for 
another round.
Results
Ninety-two (98.9%) of the 93 panelists who participated in 
the local meetings responded to the first and second rounds 
of the survey. Out of these, 59.8% were women, mean age 
was 47.6 ± 8.6 years, with a median of 18.5 years (IQR: 
10–55) of experience in the management of acromegaly.
The survey had high internal consistency (Cα > 0.8) and 
inter-rater reliability  (ri > 0.7), overall and in each of the 
blocks (Table 1). There was no great variability between the 
two rounds of the survey (relative increase of VC = 6.5%), 
and thus, a third round was not necessary.
The Spearman coefficient  (rs = 0.985, p < 0.001 for the 
overall survey) and Kappa index (k = 0.962, p < 0.001 for 
the overall survey) values were high, due to the low number 
of statements modified in round 2 with respect to round 1.
In the first round, consensus was not achieved on 15 
(24.2%) statements. Only 3 out of those 15 statements were 
resubmitted to a second round. The rest were not resubmitted 
since they described clinical practice, which would not have 
changed in subsequent rounds. Two of the non-consensus 
resubmitted statements were reformulated (S22 and 26), 
since it seemed they were not clear, and the third one was 
resubmitted without modifications (S51), since consensus 
for this statement was almost reached in the first round and 
it was of interest to see if panelists wanted to reconsider their 
position. All three statements passed to a second round with-
out specifying the previous consensus percentage achieved.
After the second round, consensus was obtained for 49 
(47 agreement and 2 disagreement) of the 62 statements 
(79%): 15 (83.3%) in the diagnosis block (Table 2), 19 
(76%) in the treatment block (Table 3), and 15 (78.9%) in 
the follow-up block (Table 4).
Discussion
The panel of endocrinologists in our study agreed a variety 
of statements regarding the diagnosis, treatment and follow-
up of acromegaly, which can be used as guidance in the 
clinical practice (Tables 2, 3, 4). Overall, the assessment of 
the levels of IGFI is the preferred screening test for acro-
megaly. If IGFI levels range between 1 and 1.3 of the upper 
limit of normal (ULN), the test is repeated and GH after oral 
glucose tolerance test (OGTT) is also assessed. In the clini-
cal practice survey of the first phase of the program, the GH 
cut off level after a OGTT to discard acromegaly in patients 
with elevated or equivocal serum IGFI levels at diagnosis 
was set ≤ 0.4 µg/L by 53% of the surveyed endocrinologists 
and < 1 µg/L by 37% of them, depending mainly on the sen-
sitivity of the assay. Regarding treatment, surgery is the first 
choice for patients with microadenoma or macroadenoma 
with/without optical pathway compression, with pre-surgical 
SSA being indicated if surgery is delayed and/or to reduce 
anaesthesia-associated risks. If after an unsuccessful surgery 
the residual tumor is resectable, reintervention is performed, 
while SSA are administered if the residual tumor is non-
resectable. The first biochemical and clinical controls are 
performed 1–3 months after surgery, with disease remis-
sion being considered if random GH levels are < 1 µg/L or 
OGTT is < 1 or ≤ 0.4 µg/L (in the clinical practice survey 
of the first phase of the program, 60% of endocrinologists 
considered disease remission after surgery when GH after 
OGTT was ≤ 0.4 µg/L, while 30% considered it when GH 
after OGTT was < 1 µg/L, depending on the sensitivity of 
the assay).
Those statements in each block that require further expla-
nation or those for which consensus was not reached, are 
more widely discussed below.
Diagnosis
In the case of a patient suspected of having acromegaly, with 
poorly controlled diabetes and non-increased IGFI, there was 
no consensus (indeterminate) to determine GH after OGTT 
for diagnosis of acromegaly (S17), since the interpretation 
of the GH response to the OGTT when diabetes mellitus or 
Table 1  Survey consistency
Cα: Cronbach’s alpha;  ri: intra-class correlation coefficient
Round 1 Round 2
Cα (p) ri (p) Cα (p) ri (p)
TOTAL (62 items) 0.918 (< 0.001) 0.864 (< 0.001) 0.923 (< 0.001) 0.865 (< 0.001)
Diagnosis block (18 items) 0.807 (< 0.001) 0.789 (< 0.001) 0.807 (< 0.001) 0.789 (< 0.001)
Treatment block (25 items) 0.825 (< 0.001) 0.797 (< 0.001) 0.894 (< 0.001) 0.819 (< 0.001)
Follow-up block (19 items) 0.846 (< 0.001) 0.805 (< 0.001) 0.848 (< 0.001) 0.805 (< 0.001)
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impaired glucose tolerance is associated to suspected acro-
megaly may be difficult [14]; however, panelists agreed to 
repeat IGFI after improvement of metabolic control in this 
case (S18).
When IGFI values ranged between 1 and 1.3 of the ULN, 
there was consensus to repeat IGFI (S3) and to assess GH 
after OGTT (S4). Guidelines do not advise on how to pro-
ceed in this case, however, taking into account that an IGFI 
value < 1.3 ULN is the limit considered as responsive to 
medical treatment in clinical trials [15, 16], in view of clini-
cal suspicion, IGFI levels > 1.3 ULN would clearly indicate 
Table 2  Diagnosis block
P percentile, C consensus, NC non-consensus, A agreement, D disagreement, I indeterminate, IGFI insulin-like growth factor I, ULN upper limit 
of normality, GH growth hormone, OGTT oral glucose tolerance test
*Statement according to guidelines? Y: Yes; N: No; X: Not mentioned in guidelines
Statement Median (P25–P75) Median range Participants in 
median range, 
n (%)
Consensus Guidelines*
1 The screening test of choice that I use for acromegaly in 
case of clinical suspicion is the determination of IGFI
9 (9–9) 7–9 92 (100%) C-A Y
2 I consider that IGFI is of choice for the diagnosis of 
acromegaly in patients with diabetes
8 (7–9) 7–9 71 (77.2%) C-A Y
3 If IGFI values range between 1 and 1.3 ULN, I repeat 
the IGFI determination
8 (7–9) 7–9 77 (83.7%) C-A X
4 If IGFI values range between 1 and 1.3 ULN, I deter-
mine GH after OGTT 
8 (7–9) 7–9 74 (80.4%) C-A X
5 After biochemical confirmation of acromegaly, I perform 
a pituitary MRI with gadolinium
9 (9–9) 7–9 92 (100%) C-A Y
6 In the presence of a baseline GH value between 0.4 and 
1 μg/L and IGFI > 1.3 and < 2 ULN, I determine GH 
after OGTT 
9 (8–9) 7–9 85 (92.4%) C-A Y
7 Within the study of comorbidities in acromegaly, I 
include a general biochemistry test and a complete 
assessment of pituitary reserve
9 (9–9) 7–9 92 (100%) C-A Y
8 Within the study of comorbidities in acromegaly, I per-
form a routine colonoscopy
9 (7–9) 7–9 72 (78.3%) C-A Y
9 Within the study of comorbidities in acromegaly, I 
include a routine thyroid echography
6 (4–8) 4–6 33 (35.9%) NC- I N
10 Within the study of comorbidities in acromegaly, I 
include an echocardiogram
8 (6–9) 7–9 65 (70.7%) C-A Y
11 Within the study of comorbidities in acromegaly, I 
include routine polysomnography
6 (4–7) 4–6 37 (40.2%) NC-I N
12 In the presence of a biochemical diagnosis of acromeg-
aly and an image of empty sella turcica, I assess the 
ectopic production of GHRH
8 (7–9) 7–9 73 (79.3%) C-A Y
13 I request a genetic study in patients with acromegaly and 
primary hyperparathyroidism
9 (8–9) 7–9 88 (95.7%) C-A Y
14 I request a genetic study in patients with acromegaly 
with macroprolactinoma in a first-degree relative
8 (7–9) 7–9 80 (87%) C-A X
15 I request a genetic study in patients with acromegaly 
younger than 20 years
9 (7–9) 7–9 78 (84.8%) C-A X
16 I request a genetic study in a patient with acromegaly 
and evidence of pheochromocytoma/paraganglioma
9 (8–9) 7–9 83 (90.2%) C-A X
17 For the diagnosis of acromegaly in a patient with poorly 
controlled diabetes, non-increased IGFI and acromeg-
aly suspicion, I determine GH after OGTT 
5 (2–7) 4–6 25 (27.2%) NC-I N
18 For the diagnosis of acromegaly in a patient with poorly 
controlled diabetes, non-increased IGFI and acro-
megaly suspicion, I repeat IGFI after improvement of 
metabolic control
8 (8–9) 7–9 82 (89.1%) C-A Y
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Table 3  Treatment block
Statement Median (P25–P75) Median range Participants in 
median range, 
n (%)
Consensus Guidelines*
Primary treatment
 19 I consider that treatment of first choice in acromegaly 
due to a microadenoma is surgery
9 (9–9) 7–9 89 (96.7%) C-A Y
 20 I consider that treatment of first choice in acromegaly 
due to a macroadenoma with compression of the 
visual pathway is surgery
9 (9–9) 7–9 92 (100%) C-A Y
 21 I consider that treatment of first choice in acromegaly 
due to a non-invasive macroadenoma with no visual 
pathway involvement is surgery
9 (8–9) 7–9 84 (91.3%) C-A Y
 22♯ I consider that the treatment of choice for acromegaly 
due to a non-invasive macroadenoma with no visual 
pathway involvement is the SSA
4 (2–6) 4–6 33 (35.9%) NC-I N
 22 I consider that the treatment of choice for acromegaly 
due to a non-invasive macroadenoma with no visual 
pathway involvement is the SSA instead of surgery
2 (1–3) 1–3 78 (84.8%) C-D N
 23 I consider that the treatment of choice for acromegaly 
due to a non-invasive macroadenoma with no visual 
pathway involvement and with low probability of 
recovery with surgery is surgical debulking
8 (7–9) 7–9 71 (77.2%) C-A Y
 24 I consider that treatment of choice in acromegaly due 
to invasive macroadenoma (Knosp grade III–IV) with 
no involvement of the visual pathway is SSA
6 (3–8) 4–6 33 (35.9%) NC-I Y
Pre-treatment with SSA
 25 I use pre-surgical treatment with SSA when there is 
delay in surgery
9 (8–9) 7–9 81 (88%) C-A Y
 26♯ I use pre-surgical treatment with SSA to achieve 
clinical-biochemical control
6 (4–8) 4–6 25 (27.2%) NC-I N
 26 I use pre-surgical treatment with SSA to increase the 
percentage of post-surgical biochemical control
3 (2–5) 1–3 60 (65.2%) NC-D N
 27 I use pre-surgical treatment with SSA to reduce 
anesthesia-associated risks
7 (6–9) 7–9 65 (70.7%) C-A Y
Second line treatment after surgery failure
 28 In the presence of a persistent disease with potentially 
resectable post-surgical residual tumor, I prescribe 
reintervention
8 (6–9) 7–9 69 (75%) C-A Y
 29 In the presence of a persistent disease with potentially 
resectable post-surgical residual tumor, I prescribe 
SSA
6 (5–8) 4–6 29 (31.5%) NC-I N
 30 In the presence of a persistent disease with unresect-
able post-surgical residual tumor, I prescribe SSA
9 (9–9) 7–9 92 (100%) C-A Y
 31 In the presence of a patient with non-cured acromegaly 
after surgery, with no visible residual tumor by MRI, 
and IGFI > 1.5 ULN, I initiate treatment with SSA
9 (8–9) 7–9 88 (95.7%) C-A N
 32 In the presence of a patient with non-cured acromegaly 
after surgery, with no visible residual tumor by 
MRI, and IGFI < 1.5 ULN, I initiate treatment with 
cabergoline
7 (5–8) 7–9 52 (56.5%) NC-A Y
 33 I use prediction tests for SSA treatment response as a 
determinant to initiate treatment with these drugs
2 (1–3) 1–3 70 (76.1%) C-D N
 34 I assess the possible resistance to analogues treatment 
at 3 months from reaching the maximum dose
8 (6–9) 7–9 69 (75%) C-A X
 35 I consider there is biochemical resistance to SSA when 
IGFI decrease is < 50%
7 (4–8) 7–9 49 (53.3%) NC-A X
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acromegaly, while a moderate IGFI elevation from 1 to 1.3 
ULN should have to be further confirmed.
Faced with a baseline GH = 0.4–1  μg/L and 1.3 
ULN < IGFI < 2 ULN, there was consensus to determine GH 
after OGTT (S6). The Spanish guidelines state that a random 
GH < 0.04 µg/L excludes acromegaly diagnosis [6], but that 
a random elevated value does not imply its presence. Thus, 
in this case, although IGFI level is elevated (> 1.3 ULN), the 
random GH value 0.4–1 μg/L cannot be interpreted, requir-
ing, even more, the determination of GH after OGTT. A GH 
value < 1 µg/L (or ≤ 0.4 µg/L, depending on the sensitivity 
of the assay) following documented hyperglycemia during 
OGTT would rule out acromegaly [5, 6].
Although the panelists agreed to include a colonoscopy 
within the study of comorbidities (S8), following guidelines 
[5–7], during the regional meetings they argued that invasive 
tests, such as this one, should not be performed at the time 
of diagnosis but at a later time during the following year, in 
order to avoid overwhelming the patients. There was no con-
sensus for including a routine thyroid echography (S9) and 
for the inclusion of a routine polysomnography (S11) within 
the study of comorbidities. As discussed in the meetings, the 
performance of these tests depends on clinical examination 
and on the availability of the appropriate equipment, which 
might be an area to consider for improvement. In fact, the 
Endocrine Society recommends a thyroid ultrasound only 
in case of palpable thyroid nodularity [7], and all guidelines 
recommend, if symptoms are suggestive, to test for sleep 
apnea with a home overnight oximetry followed by polysom-
nography [5–7]. In this regard, participants stated during the 
meeting that they usually use the Epworth sleepiness scale 
- a short questionnaire to measure daytime sleepiness - [17] 
and refer the patient to a sleep center when necessary.
There was consensus to assess the ectopic production 
of GH–releasing hormone (GHRH) in case of biochemical 
diagnosis of acromegaly and an image of empty sella (S12). 
Primary empty sella syndrome is frequently associated to 
GH deficiency; [18] thus, the coexistence of this image with 
acromegaly might be explained by the existence of GH-
secreting pituitary microadenomas or an ectopic pituitary 
adenoma [19–21], or more likely, by an ectopic secretion 
of GHRH, usually by a bronchial carcinoid tumor [22–24]. 
Both of these explanations might apply in the case of a 
Table 3  (continued)
Statement Median (P25–P75) Median range Participants in 
median range, 
n (%)
Consensus Guidelines*
 36 I consider there is biochemical resistance to SSA when 
IGFI decrease is < 25%
8 (7–9) 7–9 73 (79.3%) C-A X
 37 I consider there is resistance to SSA when an increase 
of the tumor size occurs
9 (8–9) 7–9 86 (93.5%) C-A X
 38 In patients with acromegaly with no large residual 
tumor after surgery, who partially respond to SSA 
treatment at maximum doses, I preferentially com-
bine SSA with pegvisomant if IGFI is > 2 ULN
8 (7–9) 7–9 82 (89.1%) C-A Y
 39 In patients with acromegaly with no large residual 
tumor after surgery, who partially respond to SSA 
treatment at maximum doses, I preferentially com-
bine SSA with cabergoline if IGFI is < 2 ULN
8 (7–9) 7–9 72 (78.3%) C-A Y
 40 In the presence of women with a desire for preg-
nancy and non-cured acromegaly after surgery, with 
small intrasellar residual tumor, and the rest of the 
hypophysis function conserved, I initiate medical 
treatment with SSA
8 (6–9) 7–9 65 (70.7%) C-A Y
Radiotherapy
 41 I use radiotherapy in case of aggressive adenoma 9 (8–9) 7–9 83 (90.2%) C-A Y
 42 I use radiotherapy in patients with unresectable 
residual tumor
7 (5–8) 7–9 49 (53.3%) NC-A N
 43 I use radiotherapy in case of unresectable residual 
tumor, which does not respond to medical treatment
9 (8–9) 7–9 90 (97.8%) C-A Y
P percentile, C consensus, NC non-consensus, A agreement, D disagreement, I indeterminate, IGFI insulin-like growth factor I, ULN upper limit 
of normality, GH growth hormone, OGTT oral glucose tolerance test, SSA somatostatin analogues
♯ First round for those items undergoing two rounds
*Statement according to guidelines? Y: Yes; N: No; X: Not mentioned in guidelines
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Table 4  Follow-up block
P percentile, C consensus, NC non-consensus, A agreement, D disagreement, I indeterminate, SSA somatostatin analogues, IGFI insulin-like 
growth factor I, ULN upper limit of normality, GH growth hormone, OGTT oral glucose tolerance test
♯ First round for those items undergoing two rounds
*Statement according to guidelines? Y: Yes; N: No; X: Not mentioned in guidelines
Statement Median (P25-P75) Median range Participants in 
median range, 
n (%)
Consensus Guidelines*
44 I do the first clinical and biochemical control between 1 
and 3 months after surgery
9 (8–9) 7–9 87 (94.6%) C-A Y
45 In the post-surgical evaluation, I usually request GH after 
OGTT 
7 (5–9) 7–9 55 (59.8%) NC-A Y
46 Disease remission exists when the post-surgery random 
GH value is undetectable (< 1 μg/L)
8 (6–9) 7–9 69 (75%) C-A N
47 Disease remission exists when the post-surgery GH 
value after OGTT is < 1 or ≤ 0.4 μg/L, according to the 
sensitivity of the GH test
9 (8–9) 7–9 85 (92.4%) C-A Y
48 I request the first post-surgical image control between 3 
and 6 months after surgery
9 (8–9) 7–9 89 (96.7%) C-A Y
49 If 3 months after surgery with apparently complete resec-
tion, the IGFI value is > 1.5 and < 2 ULN, I repeat IGFI 
at 1–3 months without initiating treatment
8 (6–9) 7–9 66 (71.7%) C-A Y
50 If 3 months after surgery with apparently complete 
resection, the IGFI value is > 1.5 and < 2 ULN, I initiate 
medical treatment
5 (3–8) 4–6 25 (27.2%) NC-I N
51♯ If 3 months after surgery with apparently complete resec-
tion, IGFI value is > 1.5 and < 2 ULN, I determine GH 
after OGTT, before initiating treatment
8 (5–9) 7–9 58 (63%) NC-A N
51 If 3 months after surgery with apparently complete resec-
tion, IGFI value is > 1.5 and < 2 ULN, I determine GH 
after OGTT, before initiating treatment
8 (5–8) 7–9 67 (72.8%) C-A N
52 The initial SSA dose depends upon the initial IGFI con-
centration; the greater IGFI, the greater initial dose
6 (3–8) 4–6 17 (18.5%) NC-I N
53 The initial SSA dose that I use is the maximum dose 3 (2–7) 1–3 49 (53.3%) NC-D N
54 After initiating treatment with SSA, the dose is adjusted 
after the third injection (before the 4th dose)
8 (8–9) 7–9 82 (89.1%) C-A X
55 I recommend the patient to have tests done right before 
the administration of the next SSA dose
9 (8–9) 7–9 81 (88%) C-A Y
56 In a patient on SSA treatment and with biochemical 
control, IGFI determines the possible reduction in dose 
or administration frequency of the drug
9 (8–9) 7–9 89 (96.7%) C-A Y
57 In patients treated with surgery and radiotherapy, from 
the 5th year onwards, I consider the possibility of 
decreasing or suspending SSA treatment to evaluate the 
effect of radiotherapy
8 (7–9) 7–9 77 (83.7%) C-A X
58 I request liver function tests after a month from initiating 
treatment with pegvisomant
9 (8–9) 7–9 87 (94.6%) C-A Y
59 I request pituitary MRI after 6 months of pegvisomant 
treatment
9 (8–9) 7–9 84 (91.3%) C-A Y
60 I request pituitary MRI after 6–12 months of SSA treat-
ment
9 (8–9) 7–9 91(98.9%) C-A Y
61 In a patient on treatment with 4 mg/week of cabergoline, 
with no diabetes or hypertension, and with normal ini-
tial echocardiogram, I request another echocardiogram 
after 3 years of treatment
8 (6–9) 7–9 67 (72.8%) C-A Y
62 I don´t release an acromegaly patient cured with surgery 
and with normal hypophysis function
9 (8–9) 7–9 83 (90.2%) C-A Y
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biochemical diagnosis of acromegaly and no tumor image 
in the pituitary gland MRI [22, 25, 26].
In addition to agreement for requesting a genetic study 
in patients with primary hyperparathyroidism (S13), to rule 
out multiple endocrine neoplasia type 1 (MEN1) [5, 6], there 
was also consensus to request a genetic study in patients 
with macroprolactinoma in a first-degree relative, in patients 
younger than 20 years, and in patients with evidence of phe-
ochromocytoma/paraganglioma (S14, 15 and 16), which are 
practices not mentioned in guidelines. Acromegaly can be 
part of familial diseases other than MEN1 [27]. Heterozy-
gous loss-of-function mutations in the aryl hydrocarbon 
receptor interacting protein (AIP) gene and mutations in the 
G-protein coupled receptor 101 (GPR101) gene predispose 
the appearance of young-onset pituitary adenomas [27]. In 
addition, although the coexistence of acromegaly with para-
gangliomas or phaeochromocytomas might be coincidental, 
it could also have common genetic basis, as the recently 
named “3PAs” syndrome (paragangliomas, phaeochromo-
cytomas and pituitary adenomas) [28, 29].
Treatment
Consensus was not reached with respect to considering SSA 
as the treatment of choice in acromegaly due to an invasive 
macroadenoma (Knosp grade III–IV) with no involvement of 
the visual pathway (S24), since the agreement was on surgi-
cal debulking as the treatment of choice for macroadenomas 
with low probability of recovery with surgery (S23). The 
American Association of Clinical Endocrinologists (AACE) 
guidelines also state that a role of primary medical therapy 
with SSA has been suggested in patients with macroadeno-
mas who have no local mass effects and a minimal chance 
of surgical cure [5]. The Spanish treatment algorithm, when 
surgery will not cure the disease, gives as alternative treat-
ment choice either SSA or surgery, as well as RT [6].
There was no consensus on the use of pre-surgical treat-
ment with SSA to increase the percentage of post-surgical 
biochemical control (S26), since there are studies showing 
higher remission rates in patients with pre-surgical SSA than 
in those with no pre-surgical treatment [30, 31], while other 
showed no significant differences between groups (at least 
when a normal level of GH [< 1 µg/L] after OGTT is added 
to the definition of biochemical remission) [32, 33].
Consensus was not reached for prescribing SSA (S29) in 
case of persistent disease with a potentially resectable post-
surgical residual tumor, since the consensus was reached for 
perfoming reintervention (S28), in agreement with Spanish 
guidelines [6].
Consensus was not achieved to initiate treatment with 
cabergoline in patients with non-cured acromegaly after sur-
gery, with no visible residual tumor by MRI, and IGFI < 1.5 
ULN (S32). Cabergoline is specifically recommended in 
case of modest elevations of IGFI [5–7]; however, in the 
discussion that took place during the meetings, physicians 
seemed to prefer using SSA for these cases, and only use 
cabergoline in combined treatments with the baseline drug.
There was consensus on not to use prediction tests for 
SSA treatment response as a determinant to initiate treat-
ment (S33), given that the utility of acute tests for response 
prediction is questionable [34, 35].
Biochemical resistance after SSA treatment, which 
implies non-normal IGFI levels [7], was further defined. 
Consensus was not reached for an IGFI decrease < 50% 
(S35) but it was for an IGFI decrease < 25% (S36), always 
that IGFI levels stayed elevated, as the definition of SSA 
biochemical resistance. In addition, there was consensus to 
consider an increase in tumor size as SSA resistance (S37). 
During the regional meetings the participants commented on 
the need to add the tumor size to the IGFI level for an over-
all evaluation of possible SSA treatment resistance, since 
it seems that only the absence of both responses might be 
considered as a poor response or resistance [36].
There was consensus to initiate SSA treatment in women 
with a desire for pregnancy and non-cured acromegalia after 
surgery, with a small intrasellar residual tumor but preserved 
function of the rest of the pituitary gland (S40), since RT 
would be contraindicated due to possible hypopituitarism, 
which would jeopardize fertility [5, 6].
Consensus to use RT was not reached when the statement 
just mentioned unresectable tumor without further specifi-
cation (S42). Most physicians use medical treatment first, 
while RT is only used in patients not fully responding to 
surgical and medical treatments [5–7], being also recom-
mended in cases of uncontrolled macroadenomas [6].
Follow‑up
Consensus was not achieved for requesting GH after OGTT 
in the post-surgical evaluation (S45). Although guidelines 
consider performing this test [6, 7], only some physicians do 
it and only when IGFI levels interpretation is not clear (val-
ues somewhat high but close to normal limits). The Ameri-
can guidelines recommend measuring a random GH (and 
an IGFI level) at ≥ 12 weeks from surgery, while GH after 
OGTT would only be measured in patients with GH > 1 μg/L 
[7].
The panel considered disease remission when post-
surgery random GH is undetectable (S46). Published data 
and available guidelines consider remission once disease is 
under control and random GH value is < 1 μg/L. [5, 6, 37] 
Disease remission is also determined when post-surgery GH 
value after OGTT is < 1 or ≤ 0.4 μg/L (S47), as stated in 
guidelines [5, 6, 37].
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If 3 months after surgery with apparently complete resec-
tion, the IGFI value is > 1.5 and < 2 ULN, there was con-
sensus to repeat IGFI at 1-3 months (S49), as according to 
guidelines [5, 6], and to determine GH after OGTT (S51) 
before initiating treatment; thus, no-consensus on initiating 
medical treatment directly (S50).
There was no consensus with respect to the initial SSA 
dose; whether it should depend upon the initial IGFI con-
centration (S52) or be the maximum possible dose (S53). 
Guidelines mention conventional doses and approved start-
ing doses [5–7], and when using long half-life SSA, the 
Spanish guidelines recommend starting at medium dose and 
adjust according to response [6]. On the other hand, partici-
pants agreed to adjust the SSA dose after the third injection 
(S54), which is not mentioned in guidelines.
The study participants agreed to request a pituitary MRI 
after 6 months of pegvisomant treatment (S59), despite 
the infrequent coincidence of treatment and tumor growth 
[38], and after 6–12 months of SSA treatment (S60), and to 
request an echocardiogram after 3 years of treatment with 
cabergoline (4 mg/week) (S61).
As agreed by the panel, those patients who are consid-
ered cured after surgery (with normal hypophysis function) 
are not released in the clinical practice (S62). Although not 
explicitly, Spanish guidelines also seem to recommend not to 
do so, since they state that after confirmation of post-surgery 
disease control, patients should be followed periodically 
with serial determinations of GH and IGFI every 6 months 
at the beginning and yearly later on [6].
In conclusion, overall, most Spanish endocrinologists fol-
low the clinical guidelines; thus, the clinical practice is quite 
homogeneous and participants agreed on most key aspects 
to take into consideration when managing acromegaly in 
the clinical practice. The lack of adherence to some of the 
guidelines´ recommendations in some practices may be 
accounted for by certain limitations in resources and another 
way of managing patients, which made up for such lack, 
as it occurred in the case of polysomnographies, although 
other times reflected preferences of Spanish physicians, 
such as using SSAs instead of cabergoline for modest IGFI 
elevations.
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